Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer

被引：0

作者：

Dowlati, A. ^{[1
,2
,13
]}

Chiang, A. C. ^{[3
]}

Cervantes, A. ^{[4
]}

Babu, S. ^{[5
]}

Hamilton, E. ^{[6
]}

Wong, S. F. ^{[7
]}

Tazbirkova, A. ^{[8
]}

Sullivan, I. G. ^{[9
]}

van Marcke, C. ^{[10
]}

Italiano, A. ^{[11
]}

Patel, J. ^{[12
]}

Mekan, S. ^{[12
]}

Wu, T. ^{[12
]}

Waqar, S. N. ^{[13
]}

机构：

[1] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[2] Case Western Reserve Univ, Cleveland, OH USA

[3] Yale Sch Med, New Haven, CT USA

[4] Univ Valencia, INCLIVA Inst Invest Sanitaria, Valencia, Spain

[5] Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Andrew Love Canc Ctr, Geelong, Vic, Australia

[8] Pindara Private Hosp, Benowa, Australia

[9] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[10] Clin Univ St Luc, Brussels, Belgium

[11] Inst Bergonie, Bordeaux, France

[12] Gilead Sci Inc, Foster City, CA USA

[13] Washington Univ, Sch Med, St Louis, MO USA

来源：

关键词：

second-line; small cell lung cancer; Trop-2edirected; antibodyedrug conjugate;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA04.04

引用

页码：S16 / S16

页数：1